Antidepressants Compared: SSRIs, SNRIs, TCAs, and MAOIs

Only 37 Percent Respond the First Time

The STAR*D trial — Sequenced Treatment Alternatives to Relieve Depression — enrolled 4,041 outpatients with non-psychotic major depressive disorder across 23 US clinical sites between 2001 and 2004. Its findings reshaped clinical expectations: only 36.8% of patients achieved remission on the first antidepressant (citalopram), and the cumulative remission rate after four sequential treatment steps reached just 67%. Each treatment step that failed reduced the probability of eventual remission and increased the risk of relapse even after achieving it. Antidepressant prescribing is not a solved problem; it is a systematic process of informed trial.

Antidepressant Class Mechanisms

SSRIs: Efficacy, Side Effects, and Differences

Six SSRIs are available in most markets: fluoxetine, sertraline, escitalopram, citalopram, paroxetine, and fluvoxamine. A landmark 2018 Lancet network meta-analysis of 522 trials and 116,477 participants found all SSRIs superior to placebo, with escitalopram and sertraline showing the best combination of efficacy and tolerability. Clinically significant differences exist despite the shared mechanism:

• Fluoxetine: longest half-life (2 days; active metabolite norfluoxetine: 7–14 days) — fewest discontinuation symptoms, safest in non-adherent patients, requires 5-week washout before MAOI.
• Paroxetine: strongest anticholinergic effects, most severe discontinuation syndrome, highest sexual dysfunction rate (approximately 43%).
• Sertraline: best evidence base in cardiovascular populations; widest indication range (depression, PTSD, OCD, panic, social anxiety, PMDD).
• Escitalopram: highest selectivity for SERT, fewest drug interactions, generally preferred starting point.

Sexual Dysfunction: The Undertreated Side Effect

Sexual dysfunction — decreased libido, delayed orgasm, ejaculatory delay, anorgasmia, decreased arousal — is the most common reason patients discontinue antidepressants unilaterally. Rates vary substantially by agent.

Management strategies include dose reduction, switching to bupropion or mirtazapine, adding bupropion to existing SSRI, or scheduled drug holidays (effective for delayed orgasm but risks discontinuation symptoms). The problem is undertreated because it is underasked.

TCAs and MAOIs: Power with Price

Tricyclic antidepressants predate SSRIs and remain among the most potent available antidepressants — meta-analyses suggest modest efficacy advantages over SSRIs in severely depressed inpatients. Their use is limited by side effect profiles: anticholinergic effects (dry mouth, constipation, urinary retention, confusion in elderly), antihistaminergic sedation, alpha-1 blockade (orthostatic hypotension), and the critical concern of cardiac sodium-channel blockade producing arrhythmia in overdose. A 10-day TCA supply can be lethal, making them unsuitable for patients with active suicidal ideation without close monitoring.

MAOIs — the first antidepressants developed (from tuberculosis drug iproniazid) — show particular efficacy in atypical depression (mood reactivity, hypersomnia, leaden paralysis, rejection sensitivity) and treatment-resistant cases unresponsive to multiple SSRIs/SNRIs. Irreversible MAOIs require strict dietary tyramine restriction because tyramine, normally metabolized by MAO in the GI tract, causes massive catecholamine release if MAO is blocked — producing potentially fatal hypertensive crisis. The transdermal selegiline patch at lower doses bypasses GI MAO and requires less restriction. Food restrictions remain a significant barrier to MAOI use in clinical practice. The dietary demands are real, not theoretical.

Switching and Washout Strategies

• Cross-taper: Gradual reduction of current agent while escalating new agent. Minimizes discontinuation symptoms and brief under-treatment. Most common approach between SSRIs/SNRIs.
• Direct switch: Stop old drug, start new drug next day. Practical for agents with long half-lives (fluoxetine). Higher risk of discontinuation symptoms with short-half-life agents.
• MAOI washout: Two-week washout required before starting an MAOI (5 weeks after fluoxetine). Two-week washout required after stopping an MAOI before starting any serotonergic agent. The washout is non-negotiable. Serotonin syndrome — fever, clonus, agitation, hyperreflexia — can be life-threatening.

SSRI Discontinuation Syndrome

Abrupt discontinuation of SSRIs or SNRIs — particularly short-half-life agents like paroxetine and venlafaxine — produces a withdrawal-like syndrome within 2–4 days. Symptoms include:

• FINISH mnemonic: Flu-like symptoms, Insomnia, Nausea, Imbalance/dizziness, Sensory disturbances ("brain zaps"), Hyperarousal/anxiety
• Duration: typically 1–2 weeks, but can persist for months with paroxetine or venlafaxine
• Management: gradual taper (minimum 4 weeks for short-half-life agents), switching to fluoxetine for cross-taper, symptomatic treatment with antihistamines for sleep or ondansetron for nausea

Ketamine and Esketamine: A Different Mechanism

Racemic ketamine (IV) and esketamine (intranasal, FDA-approved 2019 as Spravato) represent a mechanistic departure from monoamine-based antidepressants. Ketamine is an NMDA receptor antagonist that produces antidepressant effects within hours — contrast to 4–6 weeks for SSRIs. The mechanism involves rapid synaptogenesis in the prefrontal cortex via AMPA receptor potentiation and BDNF-mTOR signaling rather than monoamine transporter blockade.

Esketamine is approved for treatment-resistant depression and major depression with acute suicidal ideation. It must be administered in a certified healthcare setting with monitoring for 2 hours post-dose due to dissociative effects. Cost (approximately $800–900 per dose), restricted administration, and uncertain long-term maintenance scheduling limit its current reach — but its rapidity of effect offers a genuinely new option for patients in acute crisis. The mechanism is the message: depression may not be primarily a monoamine disorder.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting, changing, or stopping any medication.